GlassScriptPhysician profile
Bita Jalilizeinali
NPI 1710006275
$3,535.32
in general payments reported to CMS, 2019-2025
32 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.93 · 2022: $372 · 2023: $661 · 2024: $1,090 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.23 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.77 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $370.15 | 2024-2025 | Reblozyl, Onureg |
| Pfizer INC. | $271.52 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $258.92 | 2023-2025 | |
| Incyte Corporation | $208.97 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Sobi, INC | $202.22 | 2024-2025 | |
| Janssen Biotech, INC. | $153.37 | 2024-2025 | Carvykti, Rybrevant, Tecvayli |
| Regeneron Pharmaceuticals, INC. | $126.14 | 2023-2024 | |
| Gamida Cell INC. | $119.81 | 2025 | Omisirge |
| Beone Medicines USA, INC. | $111.91 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $105.22 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $101.02 | 2022-2025 | Cresemba, Xospata |
| Astrazeneca Pharmaceuticals LP | $99.39 | 2024-2025 | |
| Daiichi Sankyo INC. | $99.12 | 2024-2025 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $91.28 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $83.38 | 2023 | Monjuvi |
| Genzyme Corporation | $78.44 | 2021-2023 | |
| Stemline Therapeutics INC. | $77.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $72.88 | 2023-2025 | Tazverik |
| Blueprint Medicines Corporation | $70.50 | 2022-2023 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $59.10 | 2025 | Revuforj |
| Rigel Pharmaceuticals, INC. | $58.80 | 2023-2024 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $57.79 | 2022-2024 | Iclusig |
| Gilead Sciences, INC. | $55.59 | 2025 | Yescarta |
| Adc Therapeutics America, INC. | $31.52 | 2023 | |
| Geron Corporation | $26.96 | 2025 | Rytelo |
| Amgen INC. | $25.37 | 2022 | |
| Glaxosmithkline, LLC. | $24.88 | 2025 | Jemperli, Zejula |
| Servier Pharmaceuticals LLC | $24.10 | 2021 | |
| Agios Pharmaceuticals, INC. | $23.53 | 2024 | |
| Epizyme, INC. | $23.24 | 2022 | |
| Genmab U.S., INC. | $19.86 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bita Jalilizeinali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.